Patents Assigned to Genentech
  • Publication number: 20130253175
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 26, 2013
    Applicant: GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Patent number: 8541376
    Abstract: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: September 24, 2013
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Hans-Peter Gerber, Joe Kowalski, Maria Teresa Pisabarro, Daniel Eric Sherman
  • Patent number: 8541178
    Abstract: Methods to detect, characterize, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by immunoaffinity bead separation, chromatography, and mass spectrometry are disclosed; Ab-(L-D)p??I wherein Ab is an antibody; D is a drug moiety; L is a linker covalently attached to Ab, and covalently attached to D; and p is 1, 2, 3, 4, 5, 6, 7, or 8.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: September 24, 2013
    Assignee: Genentech, Inc.
    Inventors: Surinder Kaur, Ola Saad, Keyang Xu
  • Publication number: 20130243753
    Abstract: The invention provides anti-Axl antibodies and methods of using the same.
    Type: Application
    Filed: December 7, 2012
    Publication date: September 19, 2013
    Applicant: GENENTECH, INC.
    Inventors: Lin Pei, Yan Wu, Xiaofen Ye
  • Publication number: 20130243750
    Abstract: This invention provides anti-IgE antibodies that bind to the M1? segment of a human IgE and their use in treating and preventing IgE-mediated disorders, as well as kits comprising the anti-IgE antibodies.
    Type: Application
    Filed: January 30, 2013
    Publication date: September 19, 2013
    Applicant: Genentech, Inc.
    Inventors: Heleen Scheerens, Jeffrey Mark Harris, John Matthews, Wendy Sue Putnam, X. Charlene Liao
  • Patent number: 8536118
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventors: Monica Kong-Beltran, Dineli M. Wickramasinghe
  • Patent number: 8535670
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventor: Somasekar Seshagiri
  • Patent number: 8535675
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • Patent number: 8536161
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Lori Friedman
  • Patent number: 8535912
    Abstract: The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventor: Junichiro Sonoda
  • Publication number: 20130237690
    Abstract: Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea.
    Type: Application
    Filed: April 25, 2013
    Publication date: September 12, 2013
    Applicant: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona M. O'Leary
  • Publication number: 20130236930
    Abstract: A process is described for producing a polypeptide heterologous to E. coli wherein E. coli cells comprising nucleic acid encoding the polypeptide are cultured in a culture medium while feeding to the culture medium a transportable organophosphate, such that the nucleic acid is expressed. The polypeptide is then recovered from the cells.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 12, 2013
    Applicant: Genentech, Inc.
    Inventors: Woo-Lam Susan Leung, James R. Swartz
  • Publication number: 20130230522
    Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
    Type: Application
    Filed: February 5, 2013
    Publication date: September 5, 2013
    Applicant: Genentech, Inc.
    Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
  • Patent number: 8524865
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: September 3, 2013
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • Publication number: 20130225620
    Abstract: Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Application
    Filed: August 24, 2012
    Publication date: August 29, 2013
    Applicant: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, James Crawford, Wendy Lee, Simon Mathieu, Joachim Rudolph
  • Publication number: 20130224193
    Abstract: Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 29, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Publication number: 20130224194
    Abstract: Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 29, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Publication number: 20130225557
    Abstract: Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 29, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Patent number: 8518970
    Abstract: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: August 27, 2013
    Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Jonathan Bayldon Baell, Chinh Thien Bui, Peter Colman, Danette A. Dudley, Wayne J. Fairbrother, John A. Flygare, Guillaume Laurent Lessene, Chudi Ndubaku, George Nikolakopoulos, Carl Steven Rye, Brad Edmund Sleebs, Brian John Smith, Keith Geoffrey Watson, Steven W. Elmore, Andrew M. Petros, Andrew J. Souers, Peter Czabotar
  • Publication number: 20130216532
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 22, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.